康寧傑瑞製藥(09966.HK)聯手廣東東陽光共同開發抗腫瘤聯合療法
格隆匯5月28日丨康寧傑瑞製藥(09966.HK)宣佈,江蘇康寧傑瑞與廣東東陽光於2020年5月28日訂立一份合作協議。根據該協議,雙方同意共同開發CT053與KN046用於人類實體瘤領域的抗腫瘤聯合療法。
根據2020年廣東東陽光協議,雙方將成立一個聯合開發委員會,並在聯合開發委員會主導下,就CT053與KN046的組合產品用於治療HCC適應症和肺癌適應症的臨牀前研究、臨牀試驗申請、臨牀試驗、接受檢查、上市申請、商業化生產和銷售等環節進行合作。合作分兩個階段進行。第一階段由2020年廣東東陽光協議生效之日起並持續至完成協定的臨牀試驗並取得HCC及肺癌領域的臨牀研究成果之日止。第二階段為自合作第一階段後起至組合產品在中國大陸地區取得首個上市許可之日後15年止。根據合作第一階段的臨牀研究結果,雙方將就合作第二階段討論合作模式和開發方案,並另行簽訂補充協議。
據悉,KN046是集團研發的全球創新的程序性死亡配體1("PD-L1")/細胞毒性T淋巴細胞相關蛋白4("CTLA-4")雙特異性抗體。KN046同時靶向兩個臨牀驗證的免疫檢查點,PD-L1及CTLA-4。KN046的臨牀前研究及臨牀試驗已顯示出良好的安全性,且I期臨牀試驗的初步結果亦表明療效可觀。KN046目前正在進行對非小細胞肺癌(NSCLC)、三陰乳腺癌(TNBC)、食管鱗狀細胞癌(ESCC)及胰腺癌的多項II期臨牀試驗。該等臨牀試驗結果將於各種場合(包括醫學會議)發佈。KN046有望成為第二代免疫腫瘤治療藥物的基石藥物之一。
CT053(對甲苯磺酸寧格替尼)是廣東東陽光自主研發的多靶點小分子激酶抑制劑。它一方面可以通過抑制肝細胞生長因子(HGF)╱酪氨酸蛋白激酶(c-Met)和生長停滯特異性6(Gas6)/AXL╱Mer而阻斷有絲分裂原激活的蛋白激酶(MAPK)╱細胞外信號調節激酶(ERK)和磷酸肌醇3-激酶(PI3K)/蛋白激酶B(AKT)癌症信號通路傳導,直接抑制腫瘤生長。另一方面,它可以通過抑制血管內皮生長因子(VEGF)/血管內皮生長因子受體2(VEGFR2)而阻斷腫瘤新生血管的形成,抑制腫瘤細胞的生長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.